They are: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cancer-treatment-any-solid-tumor-specific-genetic-feature https://www.fda.gov/

They are: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cancer-treatment-any-solid-tumor-specific-genetic-feature https://www.fda.gov/news-events/press-announcements/fda-appr... https://en.wikipedia.org/wiki/Tissue-agnostic_cancer_drug https://en.wikipedia.org/wiki/Tissue-agnostic_cancer_drug If by "game" you mean rigorous regulatory process to ensure safety and efficacy, then yeah. Different monoclonal antibodies even with the same target can behave differently. You'd have to specifically design a trial and seek approval for an indication like the one you described. Which people have done and are doing. It's an exciting field of research!